Substance P is elevated in areas of active periodontal disease and bone loss, driving neurogenic inflammation, and could potentially be targeted therapeutically to manage gum disease and its systemic effects.
Highest SP levels in active disease sitesGingival crevicular fluid from areas with active periodontal disease and bone loss contains the highest substance P concentrations, directly linking this neuropeptide to disease activity
What the researchers found
Substance P levels in gingival crevicular fluid are highest in areas with active periodontal disease and bone loss. SP contributes to periodontal pathology through multiple mechanisms: triggering neurogenic inflammation, modulating immune responses, promoting bone resorption, and sustaining pain in vulnerable tissues. SP expression during disease progression may represent a risk factor for systemic inflammatory diseases like chronic arthritis. SP also plays roles in tissue regeneration, suggesting it could be both a therapeutic target and a regenerative tool.
Why it matters
Periodontal disease affects nearly half of adults and is increasingly linked to systemic conditions including heart disease, diabetes, and arthritis. Understanding that the neuropeptide substance P drives gum inflammation and bone loss opens new therapeutic avenues beyond traditional mechanical cleaning and antibiotics. NK1 receptor antagonists (substance P blockers) already exist for other conditions and could potentially be repurposed for periodontal management, representing a novel neuropeptide-targeted approach to oral health.
How the study worked
Narrative review searching PubMed/MEDLINE and SCOPUS for published articles on substance P's role in inflammation and periodontal disease. Search terms included "substance p AND periodontal*" AND "therapeutics." Eligible full-text articles were retrieved and data extracted on SP's role in periodontal health, disease, and therapy.
What this study cannot tell us
This is a narrative review without systematic methodology or quantitative analysis. Most evidence for substance P's role comes from observational studies measuring SP levels in gum fluid, which cannot establish causation. The therapeutic potential of targeting SP in periodontal disease is speculative — no clinical trials of NK1 antagonists for gum disease have been conducted. The dual role of SP in both inflammation and regeneration makes therapeutic targeting complex.
How to read the evidence
This is a narrative review summarizing observational and mechanistic studies. While it provides a comprehensive overview of substance P's role in periodontal disease, the therapeutic implications are largely hypothetical and await clinical validation.
When this study was published
Published in 2024, this review synthesizes current understanding of substance P in periodontal disease and proposes future therapeutic directions aligned with the growing field of neuropeptide-targeted medicine.
The bigger picture
The connection between neuropeptides and chronic inflammatory diseases is a rapidly growing field. Substance P's role in periodontal disease illustrates how the nervous system directly influences inflammatory and immune processes — the concept of neurogenic inflammation. Since periodontal disease is one of the most common chronic inflammatory conditions worldwide, targeting its neuropeptide drivers could have significant public health impact. This is especially relevant given the growing evidence linking oral inflammation to cardiovascular disease, diabetes, and neurodegenerative conditions.
Questions still open
- Could locally applied NK1 receptor antagonists reduce periodontal inflammation and bone loss in clinical trials?
- Does treating periodontal disease reduce systemic substance P levels and improve outcomes in conditions like arthritis?
- Can substance P be selectively manipulated to promote tissue regeneration while blocking its inflammatory effects?
Common questions
What is substance P and why does it matter for gum health?
Could gum disease affect other parts of the body through substance P?
Read the original research
Substance P-A neuropeptide regulator of periodontal disease pathogenesis and potential novel therapeutic entity: A narrative review.
Journal of Indian Society of Periodontology, 28(3), 284-289
Citation
Jayanthi, A; Tiwari, D; Puzhankara, L. (2024). Substance P-A neuropeptide regulator of periodontal disease pathogenesis and potential novel therapeutic entity: A narrative review.. Journal of Indian Society of Periodontology, 28(3), 284-289. https://doi.org/10.4103/jisp.jisp_56_24